Use of High Dose Cyclophosphamide in Combination with Immune Therapeutics in Anti-Cancer Therapy

Cyclophosphamide and especially high-dose cyclophosphamide has been used for the treatment of certain autoimmune diseases such as severe aplastic anemia. Low to intermediate doses of cyclophosphamide have also been used in combination chemotherapy for treating certain cancers and appears to work either by stopping the growth of cancer cells or by killing the cancer cells. However, remaining cancer cells, especially cancer stem cells, are able to divide and lead to relapse. More recently, immune-based therapeutics have been developed but immune tolerance appears to be the major barrier to the effectiveness of most immune-based therapeutics. Scientists at JHU have newly discovered that high-dose cyclophosphamide is effective in breaking immune tolerance; an obstacle in the use of various immune-based therapeutics for cancer. The methods include using a high-dose pulsed amount of the oxazaphosphorine drug, cyclophosphamide, either alone or in combination with other non-myeloablative therapies, such as monoclonal antibodies that selectively bind the B-cell specific antigens CD-20 and CD-22. Description (Set) Proposed Use (Set) High dose cyclophosphamide may be used as a combination therapy with monoclonal antibodies in the treatment of cancer, especially B-cell derived cancers.

Inventor(s): Brodsky, Robert A

Type of Offer: Licensing



« More Pharmaceutical Patents
« More Medical Patents

---